Traynor Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Traynor Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-37,029	Closed	-$1.46M	–	162
2016 Q4	$1.46M	Sell	37,029 -8,529	-19%	-$344K	0.97%	26
2016 Q3	$1.77M	Sell	45,558 -5,724	-11%	-$235K	1.25%	19
2016 Q2	$1.93M	Sell	51,282 -4,162	-8%	-$163K	1.51%	16
2016 Q1	$2.12M	Sell	55,444 -14,838	-21%	-$577K	1.69%	16
2015 Q4	$3.55M	Buy	70,282 +4,620	+7%	+$228K	2.55%	9
2015 Q3	$3M	Buy	65,662 +4,607	+8%	+$257K	2.59%	8
2015 Q2	$3.56M	Buy	61,055 +4,630	+8%	+$265K	2.97%	8
2015 Q1	$3.11M	Buy	56,425 +5,888	+12%	+$318K	2.99%	7
2014 Q4	$2.54M	Buy	+50,537	New	+$2.47M	2.95%	7

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Traynor Capital Management's PBE Position: Q1 2017 in Review

Traynor Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2017, closing a stake of 37,029 shares — an estimated $1.46M sold.

Traynor Capital Management first reported a position in PBE in Q4 2014 and held it in 9 quarters. The position peaked at $3.56M in Q2 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q1 2017.

Traynor Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2017 after selling out during the quarter.
Traynor Capital Management sold 37,029 Invesco Biotechnology & Genome ETF shares in Q1 2017, an estimated $1.46M.
Traynor Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2014 and held it in 9 quarters.
Traynor Capital Management's Invesco Biotechnology & Genome ETF position peaked at $3.56M in Q2 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2017.

Based on Traynor Capital Management's 13F filing for Q1 2017, filed 11 May 2017.